Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with hematological malignancies

IF 3.2 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Current Research in Translational Medicine Pub Date : 2024-08-17 DOI:10.1016/j.retram.2024.103466

Simon Planken , Ann De Becker , Tessa Kerre , Hélène Schoemans , Frédéric Baron , Carlos Graux , Ivan Van Riet , Chantal Lechanteur , Etienne Baudoux , Rik Schots , Yves Beguin , Transplant Committee of the Belgian Hematology Society.

{"title":"Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with hematological malignancies","authors":"Simon Planken , Ann De Becker , Tessa Kerre , Hélène Schoemans , Frédéric Baron , Carlos Graux , Ivan Van Riet , Chantal Lechanteur , Etienne Baudoux , Rik Schots , Yves Beguin , Transplant Committee of the Belgian Hematology Society.","doi":"10.1016/j.retram.2024.103466","DOIUrl":null,"url":null,"abstract":"<div><p>Umbilical cord blood (UCB) is an alternative source of stem cells for patients lacking a 9/10 or 10/10 HLA identical donor. However, after UCB transplantation, time to engraftment and immune recovery are prolonged, increasing the risk of fatal complications. Mesenchymal stromal cells (MSC) can support hematopoietic engraftment and have immunosuppressive effects.</p><p>The primary objective of this phase I/II multicenter study was to determine the feasibility and safety of UCB transplantation with co-infusion of third party MSC, as assessed by treatment related mortality (TRM) at day 100. Secondary objectives were engraftment, immune recovery, occurrence of graft versus host disease (GVHD), infections, disease free survival, relapse incidence and overall survival.</p><p>Eleven patients were grafted according to this protocol. Allogeneic transplantation after co-infusion appears feasible with 18 % TRM at day 100. Engraftment data show a median time of 16 days to neutrophil and 27 days to platelet recovery, which is shorter than what is usually reported after UCB transplantation. Only 1 episode of acute GVHD was reported.</p><p>In conclusion, MSC and UCB co-transplantation is feasible and might help overcome some of the drawbacks of UCB transplantation.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 4","pages":"Article 103466"},"PeriodicalIF":3.2000,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S245231862400028X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Umbilical cord blood (UCB) is an alternative source of stem cells for patients lacking a 9/10 or 10/10 HLA identical donor. However, after UCB transplantation, time to engraftment and immune recovery are prolonged, increasing the risk of fatal complications. Mesenchymal stromal cells (MSC) can support hematopoietic engraftment and have immunosuppressive effects.

The primary objective of this phase I/II multicenter study was to determine the feasibility and safety of UCB transplantation with co-infusion of third party MSC, as assessed by treatment related mortality (TRM) at day 100. Secondary objectives were engraftment, immune recovery, occurrence of graft versus host disease (GVHD), infections, disease free survival, relapse incidence and overall survival.

Eleven patients were grafted according to this protocol. Allogeneic transplantation after co-infusion appears feasible with 18 % TRM at day 100. Engraftment data show a median time of 16 days to neutrophil and 27 days to platelet recovery, which is shorter than what is usually reported after UCB transplantation. Only 1 episode of acute GVHD was reported.

In conclusion, MSC and UCB co-transplantation is feasible and might help overcome some of the drawbacks of UCB transplantation.

查看原文本刊更多论文

血液恶性肿瘤患者在接受（非）髓鞘消融治疗后联合移植脐带血和第三方间充质基质细胞的可行性

脐带血（UCB）是缺乏 9/10 或 10/10 HLA 相同供体的患者的另一种干细胞来源。然而，脐带血移植后，移植时间和免疫恢复时间延长，增加了致命并发症的风险。这项 I/II 期多中心研究的主要目的是确定联合输注第三方间充质干细胞进行 UCB 移植的可行性和安全性，并通过第 100 天的治疗相关死亡率（TRM）进行评估。次要目标包括移植、免疫恢复、移植物抗宿主疾病（GVHD）发生率、感染、无病生存率、复发率和总生存率。联合输注后进行异体移植似乎是可行的，第100天的TRM为18%。移植数据显示，中性粒细胞恢复的中位时间为16天，血小板恢复的中位时间为27天，这比通常报告的UCB移植时间要短。总之，间充质干细胞和 UCB 联合移植是可行的，可能有助于克服 UCB 移植的一些缺点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

7.00

自引率

4.90%

发文量

审稿时长

45 days

期刊介绍： Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.